For Research Purposes Only · Not For Human Consumption

Home/Buy/Retatrutide 10mg
≥98% (HPLC-UV)
Lot LX-2501Summer Sale · 30% Off
Retatrutide 10mg vial
Third-party tested
CoA available
UK dispatched
CoA verified

Metabolic Research

Buy Retatrutide 10mg UK | Research Grade

Triple-receptor GLP-1, GIP and glucagon agonist. Retatrutide — often shortened to 'Reta' — is the most advanced metabolic research peptide, supplied as lyophilised powder with batch-matched CoA.

£59.99

£85.70

In stock

Inc. VAT · Free UK shipping on this order

1

SSL encrypted · Same-day dispatch before 6pm · CoA on this lot

Order before 6pm tomorrow for same-day dispatch

Independently HPLC-tested. Lot-matched CoA available on request — quote your batch and order ID.

What ships with your order

  • 011 × Retatrutide 10mg — lyophilised, sealed glass vial
  • 02Signed CoA — batch LX-2501, HPLC-UV + mass-spec
  • 03Royal Mail Tracked 24 — same-day dispatch before 6pm, Mon–Fri
Research Compound

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide entered Phase 2 clinical trials in 2022 and Phase 3 trials in 2023. In Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest dose demonstrated a mean body weight reduction of 17.5% at 24 weeks. Peptides UK supplies retatrutide strictly for in-vitro and preclinical laboratory research. This compound is not approved for human use and is not a licensed medicine.

Research areas

  • GLP-1/GIP/glucagon receptor signalling
  • Metabolic pathway modelling
  • Adipogenesis & lipid metabolism
  • In-vitro obesity models
Compound Profile

Retatrutide 10mg — mechanism, research applications & compound data

Retatrutide (LY3437943) — often shortened by researchers to "Reta" — is the most advanced triple-agonist research peptide currently in clinical development, simultaneously targeting the GLP-1, GIP and glucagon receptors. Peptides UK supplies pharmaceutical-grade Retatrutide 10mg lyophilised powder, independently HPLC-verified to ≥98% purity and shipped same-day from Manchester with a batch-matched Certificate of Analysis.

01

Buy Retatrutide UK — is "Reta" the same compound?

Yes. "Reta" is simply the informal shorthand the research community uses for Retatrutide — the two terms refer to the exact same triple GLP-1/GIP/glucagon receptor agonist (LY3437943). Whether you're searching "retatrutide uk", "buy retatrutide uk", "retatrutide for sale uk", "retatrutide peptide uk" or simply "buy reta", this 10mg vial is Peptides UK's standard retatrutide listing — dispatched same-day from Manchester with full batch traceability and a ≥98% HPLC-verified, CoA-backed Certificate of Analysis. We also stock a separate Retatrutide 20mg vial for laboratories running extended, longer-duration protocols.

02

What is Retatrutide and why is it significant in metabolic research?

Retatrutide is a novel synthetic peptide developed by Eli Lilly as the first investigational triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. Unlike single-agonist incretin mimetics such as semaglutide or dual agonists such as tirzepatide, retatrutide engages all three metabolic receptors in parallel — producing a markedly broader signalling profile in in-vitro models of energy expenditure, adipogenesis and hepatic lipid metabolism. Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported a mean 17.5% body weight reduction at 24 weeks at the highest dose cohort, positioning retatrutide as the most potent investigational compound in its class. Phase 3 trials commenced in 2023.

03

Retatrutide mechanism of action: triple-receptor agonism explained

GLP-1 receptor agonism slows gastric emptying and enhances glucose-dependent insulin secretion in pancreatic beta-cell models. GIP receptor agonism amplifies postprandial insulin release and modulates adipocyte lipid storage. Glucagon receptor agonism increases hepatic glucose output and, critically, drives energy expenditure and lipolysis. By converging all three receptor pathways into a single molecule with a fatty-acid moiety for extended half-life, retatrutide produces a synergistic metabolic profile not achievable with mono- or dual-agonist peptides. This makes it a uniquely important compound for in-vitro receptor pharmacology, GPCR signalling studies and adipose-tissue research models.

04

Research applications for Retatrutide 10mg

The 10mg vial supports a wide range of preclinical and in-vitro research designs, including GLP-1/GIP/glucagon receptor binding assays, cAMP/β-arrestin recruitment studies, adipocyte differentiation and lipolysis modelling, hepatocyte glucose-output assays, mitochondrial biogenesis and thermogenesis pathway research, comparative incretin receptor pharmacology versus semaglutide and tirzepatide, and pharmacokinetic modelling of fatty-acid-acylated peptide analogues. Researchers comparing single-, dual- and triple-agonist signalling profiles routinely use this compound as the reference triple-agonist standard.

05

Reconstitution, dosing volumes and handling for Retatrutide

Reconstitute the lyophilised powder with bacteriostatic water (0.9% benzyl alcohol). Add solvent slowly down the inside wall of the vial — never inject directly onto the lyophilised cake. Allow the powder to dissolve gently at room temperature for 60–90 seconds; do not shake. A common reconstitution volume is 1ml or 2ml of bacteriostatic water per 10mg vial depending on research protocol concentration. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days. Do not refreeze. Always allow the unopened lyophilised vial to reach room temperature before puncturing the septum to prevent condensation entering the vial and compromising stability.

06

Quality assurance and Certificate of Analysis

Every Retatrutide 10mg lot dispatched by Peptides UK is independently analysed by Janoshik Analytical or Aspen Bioanalytics — two of Europe's most respected third-party peptide testing laboratories. Each batch is tested for HPLC-UV purity (≥98%), mass-spectrometry identity confirmation against the published molecular weight of 4,810.5 Da, residual solvent profile, and visual integrity. The signed PDF Certificate of Analysis for the exact lot you receive is downloadable directly from this product page — not a generic placeholder, not a marketing summary. Lot traceability is auditable.

07

Why UK researchers choose Peptides UK for Retatrutide

Peptides UK is a fully UK-based research peptide supplier headquartered in Manchester. We hold stock in temperature-controlled storage, dispatch the same working day for orders placed before 6pm GMT, ship via Royal Mail Tracked 24 in insulated mailers with ice packs, and provide signed batch CoAs from independent laboratories on every vial. No grey-market sourcing, no overseas customs delays, no fabricated documentation — just verifiable analytical data on UK-stocked research compounds at competitive prices.

Related search terms

  • retatrutide 10mg uk
  • retatrutide buy uk
  • buy retatrutide
  • retatrutide uk
  • buy retatrutide uk
  • retatrutide uk buy
  • retatrutide buy
  • retatrutide for sale uk
  • retatrutide peptide uk
  • buy retatrutide peptide uk
  • buy reta uk
  • buy reta
  • reta 10mg
  • where to buy retatrutide
  • where can i buy retatrutide uk
  • retatrutide 10mg buy
  • research peptide retatrutide
  • LY3437943 research compound
  • triple agonist GLP-1 GIP glucagon
  • retatrutide HPLC purity
  • retatrutide CoA
  • Eli Lilly retatrutide research
  • retatrutide lyophilised powder
References & further reading

Primary sources cited on this page

Retatrutide (development code LY3437943, informally "Reta") is a synthetic 39-residue peptide developed by Eli Lilly, engineered as a triple agonist of the glucagon (GCGR), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is investigational and has not been approved by any regulator.

Regulatory & compliance notice

This product is supplied strictly for in-vitro laboratory research. It is not a licensed medicine in the United Kingdom, is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency for human or veterinary use, and is not intended to diagnose, treat, cure or prevent any disease. Nothing on this page constitutes medical advice.

External links point to primary literature or regulatory records and open in a new tab. Citations are provided so the reader can independently verify every factual claim made on this page. Last reviewed 22 July 2026.

Certificate of Analysis

Retatrutide 10mg

Independent lab
Janoshik Analytical
Batch number
LX-2501
Method
HPLC-UV + MS
Result
≥98% (HPLC-UV)
Download CoA (PDF) — Retatrutide 10mgView full Certificate of Analysis for batch LX-2501

The CoA you download is the exact certificate produced for this lot — no edits.

Storage & handling

Keep it stable, keep it sterile

  • Storage: Store lyophilised powder at -20°C in a sealed vial. Protect from light and moisture. Allow the vial to reach room temperature before opening to prevent condensation entering the vial. Do not store in a frost-free freezer.
  • Reconstitution: Reconstitute using bacteriostatic water (0.9% benzyl alcohol). Add solvent slowly down the side of the vial — do not shake. Allow to dissolve gently at room temperature.
  • Reconstituted stability: Once reconstituted, store at 2–8°C (refrigerated). Use within 28 days. Do not refreeze after reconstitution.
  • Shipping: All vials are dispatched in insulated mailers with ice packs to maintain cold chain during Royal Mail Tracked 24 transit.
+ Add Bacteriostatic Water (£4.99) →
FAQ

Retatrutide 10mg — common questions

Related

Researchers also ordered

View all →
  • Summer Sale · 30% Off
    Retatrutide 20mg vial

    Metabolic Research

    Retatrutide · 20mg

    Higher-dose triple-receptor GLP-1, GIP and glucagon agonist for extended research. Retatrutide (Reta) as lyophilised powder with batch-matched CoA.

    ≥98% HPLCIn Stock

    £99.99£142.84

  • Essential
    Bacteriostatic Water 3ml vial

    Accessories / Reconstitution

    Bacteriostatic Water · 3ml

    0.9% benzyl alcohol bacteriostatic water for peptide reconstitution. Pharmaceutical-grade, sterile-filtered 3ml vial.

    ≥98% HPLCIn Stock

    £4.99

  • Top Rated
    BPC-157 5mg vial

    Recovery / Healing

    BPC-157 · 5mg

    Body Protection Compound-157. Widely researched for tissue repair, gut health and joint recovery.

    ≥98% HPLCIn Stock

    £15.99

Every batch independently tested by Janoshik Analytical and Aspen Bioanalytics before dispatch. Signed certificates available on every product page.

Third-party HPLC-UV testing Lot-matched CoA on every order Batch-traceable from dispatch

Legal notice

This product is sold strictly for in-vitro laboratory research purposes only. It is not approved for human or veterinary use, is not a drug, food, or cosmetic, and should not be misused as such. Peptides UK accepts no liability for misuse. By purchasing you confirm you are a qualified researcher aged 18 or over.

Retatrutide 10mg

£59.99£85.70